Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04468841 · ClinicalTrials.gov registry record · Phase 1
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
A Phase 1 study of Follicular Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 7
- Study locations
NCT04468841: Recruiting Phase 1 study of Follicular Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04468841 is a Phase 1 study of Follicular Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 100 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04468841, a Phase 1 study of Follicular Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to measure and test cell-free DNA (cfDNA) in the blood before, during, and after first-line treatment for follicular lymphoma. They will look at whether cfDNA levels are related to a person's response to the usual first-line treatment for follicular lymphoma. Researchers also want to understand how different genetic changes in follicular lymphoma relate to a person's response to the usual first-line treatment.
Primary Outcome
Response will be evaluated using the updated response criteria entitled, "The Lugano Classification" system. The investigator will use of the 5-point scale for visually assessing response on the pre- and end-of-treatment FDGPET/CT scans. This scale is commonly referred to as the Deauville criteria; it was developed by international experts in the field at the First International Workshop on interim-PET in Lymphoma in Deauville in 2009 and is routinely applied to patients undergoing lymphoma dire
Conditions Studied
Interventions
- DIAGNOSTIC_TEST cfDNA testing
- OTHER sample of saliva or fingernail clipping
- DIAGNOSTIC_TEST pre-treatment test specimen
- DIAGNOSTIC_TEST PET/CT, CT, or MRI testing
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (All protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT04468841 shows while recruiting
NCT04468841 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which cfDNA testing is the first listed.
NCT04468841 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04468841 about?
NCT04468841 is a clinical study titled "Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma". The researchers are doing this study to measure and test cell-free DNA (cfDNA) in the blood before, during, and after first-line treatment for follicular lymphoma. They will look at whether cfDNA levels are related to a person's response to the usual first-line treatment for follicular lymphoma. Res...
What is the current status of trial NCT04468841?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2020-07-08. Estimated completion is 2026-07.
What conditions does trial NCT04468841 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT04468841?
The interventions under investigation include: cfDNA testing (DIAGNOSTIC_TEST), sample of saliva or fingernail clipping (OTHER), pre-treatment test specimen (DIAGNOSTIC_TEST), PET/CT, CT, or MRI testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04468841?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04468841 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04468841's enrollment target sits among peer trials
100 30th of 89 higher than 57 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI